Literature DB >> 19560577

Alterations in epithelial barrier function and host defense responses in chronic rhinosinusitis.

David D Tieu1, Robert C Kern, Robert P Schleimer.   

Abstract

Chronic rhinosinusitis (CRS) is characterized by a chronic symptomatic inflammation of the nasal and paranasal sinus mucosae and is one of the most frequently reported chronic diseases in the United States, with an estimated prevalence of greater than 10% of the general population. Although the pathogenesis of CRS remains poorly understood, there is evidence for a role of bacteria and fungi, as well as the presence of a robust adaptive immune response in the upper airways and sinuses. Recent studies of CRS, as well as several other diseases in the skin and respiratory epithelium, have uncovered evidence that deficiencies in epithelial immune barrier function might compromise the interaction between the host and external immune stimuli. Recent studies suggest the hypothesis that reduced expression of antimicrobial S100 proteins, particularly psoriasin and calprotectin, might lead to increased susceptibility to bacterial and fungal colonization in patients with CRS. The main emphasis of this review will be to highlight the current literature that suggests that a defect in the expression of a broad set of epithelially derived genes might lead to barrier compromise and subsequently a dysfunctional host immune response to environmental agents in patients with CRS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19560577      PMCID: PMC2802265          DOI: 10.1016/j.jaci.2009.04.045

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  44 in total

Review 1.  Epithelium: at the interface of innate and adaptive immune responses.

Authors:  Robert P Schleimer; Atsushi Kato; Robert Kern; Douglas Kuperman; Pedro C Avila
Journal:  J Allergy Clin Immunol       Date:  2007-10-18       Impact factor: 10.793

Review 2.  The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29.

Authors:  Scott Commins; John W Steinke; Larry Borish
Journal:  J Allergy Clin Immunol       Date:  2008-04-11       Impact factor: 10.793

Review 3.  Epithelium dysfunction in asthma.

Authors:  Stephen T Holgate
Journal:  J Allergy Clin Immunol       Date:  2007-12       Impact factor: 10.793

4.  Psoriasin (S100A7) is a principal antimicrobial peptide of the human tongue.

Authors:  J E Meyer; J Harder; B Sipos; S Maune; G Klöppel; J Bartels; J-M Schröder; R Gläser
Journal:  Mucosal Immunol       Date:  2008-03-05       Impact factor: 7.313

5.  The calcium binding protein S100A9 is essential for pancreatic leukocyte infiltration and induces disruption of cell-cell contacts.

Authors:  Jürgen Schnekenburger; Verena Schick; Burkhard Krüger; Marie Pierre Manitz; Clemens Sorg; Wolfgang Nacken; Claus Kerkhoff; Andreas Kahlert; Julia Mayerle; Wolfram Domschke; Markus M Lerch
Journal:  J Cell Physiol       Date:  2008-08       Impact factor: 6.384

6.  Epithelial genes in chronic rhinosinusitis with and without nasal polyps.

Authors:  Sara L Richer; Ai Q Truong-Tran; David B Conley; Roderick Carter; David Vermylen; Leslie C Grammer; Anju T Peters; Rakesh K Chandra; Kathleen E Harris; Robert C Kern; Robert P Schleimer
Journal:  Am J Rhinol       Date:  2008 May-Jun

7.  Evidence of a role for B cell-activating factor of the TNF family in the pathogenesis of chronic rhinosinusitis with nasal polyps.

Authors:  Atsushi Kato; Anju Peters; Lydia Suh; Roderick Carter; Kathleen E Harris; Rakesh Chandra; David Conley; Leslie C Grammer; Robert Kern; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2008-04-14       Impact factor: 10.793

8.  Analysis of the individual and aggregate genetic contributions of previously identified serine peptidase inhibitor Kazal type 5 (SPINK5), kallikrein-related peptidase 7 (KLK7), and filaggrin (FLG) polymorphisms to eczema risk.

Authors:  Stephan Weidinger; Hansjörg Baurecht; Stefan Wagenpfeil; John Henderson; Natalija Novak; Aileen Sandilands; Huijia Chen; Elke Rodriguez; Grainne M O'Regan; Rosemarie Watson; Haihui Liao; Yiwei Zhao; Jonathan N W N Barker; Michael Allen; Nick Reynolds; Simon Meggitt; Kate Northstone; George D Smith; Carolin Strobl; Caroline Stahl; Thomas Kneib; Norman Klopp; Thomas Bieber; Heidrun Behrendt; Colin N A Palmer; H-Erich Wichmann; Johannes Ring; Thomas Illig; W H Irwin McLean; Alan D Irvine
Journal:  J Allergy Clin Immunol       Date:  2008-09       Impact factor: 10.793

9.  Filaggrin mutations, atopic eczema, hay fever, and asthma in children.

Authors:  Stephan Weidinger; Maureen O'Sullivan; Thomas Illig; Hansjörg Baurecht; Martin Depner; Elke Rodriguez; Andreas Ruether; Norman Klopp; Christian Vogelberg; Stephan K Weiland; W H Irwin McLean; Erika von Mutius; Alan D Irvine; Michael Kabesch
Journal:  J Allergy Clin Immunol       Date:  2008-04-08       Impact factor: 10.793

10.  Flagellin is the principal inducer of the antimicrobial peptide S100A7c (psoriasin) in human epidermal keratinocytes exposed to Escherichia coli.

Authors:  Arby Abtin; Leopold Eckhart; Michael Mildner; Florian Gruber; Jens-Michael Schröder; Erwin Tschachler
Journal:  FASEB J       Date:  2008-02-08       Impact factor: 5.191

View more
  57 in total

1.  ANTI-INFECTIVE PROTECTIVE PROPERTIES OF S100 CALGRANULINS.

Authors:  Kenneth Hsu; Chantrakorn Champaiboon; Brian D Guenther; Brent S Sorenson; Ali Khammanivong; Karen F Ross; Carolyn L Geczy; Mark C Herzberg
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2009-12-04

2.  IL-33-responsive innate lymphoid cells are an important source of IL-13 in chronic rhinosinusitis with nasal polyps.

Authors:  Joanne L Shaw; Samer Fakhri; Martin J Citardi; Paul C Porter; David B Corry; Farrah Kheradmand; Yong-Jun Liu; Amber Luong
Journal:  Am J Respir Crit Care Med       Date:  2013-08-15       Impact factor: 21.405

3.  A novel mutation of DNAH5 in chronic rhinosinusitis and primary ciliary dyskinesia in a Chinese family.

Authors:  Jing Zhang; Liping Guan; Weiping Wen; Yu Lu; Qianyan Zhu; Huijun Yuan; Yulan Chen; Hongtian Wang; Jianguo Zhang; Huabin Li
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-10-23       Impact factor: 2.503

4.  Chronic rhinosinusitis as a multifactorial inflammatory disorder.

Authors:  Stella Lee; Andrew P Lane
Journal:  Curr Infect Dis Rep       Date:  2011-04       Impact factor: 3.725

Review 5.  The barrier hypothesis and Oncostatin M: Restoration of epithelial barrier function as a novel therapeutic strategy for the treatment of type 2 inflammatory disease.

Authors:  Kathryn L Pothoven; Robert P Schleimer
Journal:  Tissue Barriers       Date:  2017-06-13

6.  Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology.

Authors:  Cezmi A Akdis; Claus Bachert; Cemal Cingi; Mark S Dykewicz; Peter W Hellings; Robert M Naclerio; Robert P Schleimer; Dennis Ledford
Journal:  J Allergy Clin Immunol       Date:  2013-04-12       Impact factor: 10.793

Review 7.  Perspectives on the etiology of chronic rhinosinusitis.

Authors:  Bruce K Tan; Robert P Schleimer; Robert C Kern
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2010-02       Impact factor: 2.064

8.  A brief history of asthma and its mechanisms to modern concepts of disease pathogenesis.

Authors:  Stephen T Holgate
Journal:  Allergy Asthma Immunol Res       Date:  2010-05-06       Impact factor: 5.764

Review 9.  A new look at the pathogenesis of asthma.

Authors:  Stephen T Holgate; Hasan S Arshad; Graham C Roberts; Peter H Howarth; Philipp Thurner; Donna E Davies
Journal:  Clin Sci (Lond)       Date:  2009-12-23       Impact factor: 6.124

10.  Gene transcription changes in asthmatic chronic rhinosinusitis with nasal polyps and comparison to those in atopic dermatitis.

Authors:  Douglas A Plager; Jane C Kahl; Yan W Asmann; Allan E Nilson; John F Pallanch; Oren Friedman; Hirohito Kita
Journal:  PLoS One       Date:  2010-07-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.